Galera Therapeutics, Inc.
GRTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GRTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRTX
Galera Therapeutics, Inc. is a clinical-stage biotechnology company that has ceased all clinical trial activity and is exploring strategic alternatives, including potential partnerships or a sale of the company, with cash of $5.5M as of 2026-03-31.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Galera Therapeutics, Inc..
Galera Therapeutics, Inc. is a clinical-stage biotechnology company that has ceased all clinical trial activity and is exploring strategic alternatives, including potential partnerships or a sale of the company, with cash of $5.5M as of 2026-03-31.
- Galera has ceased all clinical trial activity and suspended clinical development of certain product candidates [sec_mda · as of 2025-11-13].
- The company is exploring strategic alternatives, including potential partnerships or a sale, to enhance stockholder value [sec · filed 2024-09-03].
- Cash and equivalents were $5.5M as of 2026-03-31, with a net loss of $1.6M and shareholders' equity of $4.0M [latest reported financials].
- Historically, the company was focused on developing novel therapeutics to transform radiotherapy in cancer, but has not generated revenue since inception [sec · filed 2024-09-03].
- Galera has funded operations primarily through equity sales and a $117.5M Royalty Agreement with Blackstone Life Sciences, with aggregate gross proceeds of $379.9M [sec_mda · as of 2025-05-15].
What works
- The company has an existing drug supply of avasopasem for an NIH-funded investigator-sponsored trial in HR+ breast cancer, which may provide data without significant additional cost [sec_mda · as of 2025-03-31].
- Galera has engaged in discussions with numerous companies regarding potential global and regional partnerships, indicating ongoing efforts to find a strategic path forward [sec · filed 2024-09-03].
- The company has raised substantial capital historically, including $379.9M in aggregate gross proceeds, demonstrating prior investor confidence [sec_mda · as of 2025-05-15].
What to weigh
- Galera has ceased all clinical trial activity and suspended development of its product candidates, with no active pipeline [sec_mda · as of 2025-11-13].
- The company has incurred recurring losses and negative cash flows from operations since inception, with no product revenue generated [sec_mda · as of 2025-05-15].
- Cash of $5.5M as of 2026-03-31 is limited, and the company faces uncertainty in raising additional capital or deferring expenses to continue operations [sec_mda · as of 2026-03-19].
- There is no assurance that the company will successfully execute a strategic transaction or raise sufficient capital, which could lead to reduced operations or dissolution [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
Galera has ceased all clinical trial activity.
“We have ceased all clinical trial activity and have suspended the clinical development of certain of our product candidates.”
SEC MD&A · November 13, 2025
The company is exploring strategic alternatives.
“markets, all with the goal of enhancing value for our stockholders and making a positive impact in patients' lives. As part of this process, from time to time, our management has engaged in business development and/or strategic discussions with industry participants.”
SEC filings · September 3, 2024
Galera has not generated revenue since inception.
“We have not generated revenue since our inception and historically financed our operations primarily with the proceeds from issuance of equity securities and bor”
SEC filings · September 3, 2024
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Cash of $5.5M as of 2026-03-31 may not be sufficient to fund operations without additional capital or expense deferrals [sec_mda · as of 2026-03-19].
- No active pipeline — All clinical trial activity has ceased, and development of product candidates is suspended, with no near-term revenue prospects [sec_mda · as of 2025-11-13].
- Strategic transaction failure — There is no assurance that the company will successfully complete a partnership, sale, or other strategic alternative [sec · filed 2024-09-03].
- History of losses — Galera has incurred recurring losses and negative cash flows since inception, with no product revenue [sec_mda · as of 2025-05-15].
What to watch
- Outcome of strategic alternative process, including any potential partnership or sale of the company [sec · filed 2024-09-03].
- Enrollment and data from the NIH-funded investigator-sponsored trial of avasopasem in HR+ breast cancer, expected to start in first half of 2025 [sec_mda · as of 2025-03-31].
- Ability to raise additional capital or defer expenses to extend cash runway beyond current levels [sec_mda · as of 2026-03-19].
- Any updates on the I-SPY 2 consortium collaboration for a second trial in TNBC [sec_mda · as of 2025-11-13].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Galera Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Galera Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
19.4 months
D/E 1.57 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 5.3%
- Days to cover
- 1.2
- Shares short
- 2,123,783
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GRTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Galera Therapeutics, Inc.?
Galera Therapeutics, Inc. is a clinical-stage biotechnology company that has ceased all clinical trial activity and is exploring strategic alternatives, including potential partnerships or a sale of the company, with cash of $5.5M as of 2026-03-31.
What is Galera Therapeutics, Inc.'s lead drug candidate?
Galera Therapeutics, Inc.'s most advanced tracked candidate is avasopasem (Phase 1) for Hormone receptor positive (HR+) breast cancer.
Who is the CEO of Galera Therapeutics, Inc.?
Dr. John Mel Sorensen M.D. is the chief executive officer of Galera Therapeutics, Inc. (GRTX).
Where is Galera Therapeutics, Inc. headquartered?
Galera Therapeutics, Inc. (GRTX) is headquartered in Malvern, PA, United States.
What therapeutic areas does Galera Therapeutics, Inc. focus on?
Galera Therapeutics, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.